IL155431A0 - Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders - Google Patents

Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders

Info

Publication number
IL155431A0
IL155431A0 IL15543100A IL15543100A IL155431A0 IL 155431 A0 IL155431 A0 IL 155431A0 IL 15543100 A IL15543100 A IL 15543100A IL 15543100 A IL15543100 A IL 15543100A IL 155431 A0 IL155431 A0 IL 155431A0
Authority
IL
Israel
Prior art keywords
melagatran
medicament
manufacture
treatment
ischemic disorders
Prior art date
Application number
IL15543100A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL155431A0 publication Critical patent/IL155431A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15543100A 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders IL155431A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,912 US6462021B1 (en) 2000-11-06 2000-11-06 Use of low molecular weight thrombin inhibitor
PCT/SE2000/002204 WO2002036157A1 (en) 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders

Publications (1)

Publication Number Publication Date
IL155431A0 true IL155431A0 (en) 2003-11-23

Family

ID=24835453

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15543100A IL155431A0 (en) 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders

Country Status (14)

Country Link
US (1) US6462021B1 (ja)
EP (1) EP1333855A1 (ja)
JP (2) JP2004512376A (ja)
KR (1) KR20040004431A (ja)
CN (1) CN1455679A (ja)
AU (2) AU2001225625B2 (ja)
BR (1) BR0017367A (ja)
CA (1) CA2428012A1 (ja)
IL (1) IL155431A0 (ja)
MX (1) MXPA03003980A (ja)
NO (1) NO20032006L (ja)
NZ (1) NZ525487A (ja)
WO (1) WO2002036157A1 (ja)
ZA (1) ZA200303013B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0201373D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Combination therapy
SE0201374D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Pharmaceutical combination
MXPA05002662A (es) 2002-09-09 2005-09-20 Trigen Ltd Sales de metal multivalente de acidos boronicos para el tratamiento de trombosis.
US7371729B2 (en) 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
WO2008009638A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE69625230T2 (de) 1995-10-24 2003-09-04 Merck & Co., Inc. Thrombininhibitoren
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602145D0 (sv) 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9704401D0 (sv) 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9704400D0 (sv) 1997-11-28 1997-11-28 Astra Ab Porous inorganic particles as carriers for drug substances
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
WO2002036157A1 (en) 2002-05-10
JP2004512376A (ja) 2004-04-22
AU2562501A (en) 2002-05-15
ZA200303013B (en) 2004-07-16
JP2005120098A (ja) 2005-05-12
US6462021B1 (en) 2002-10-08
CN1455679A (zh) 2003-11-12
EP1333855A1 (en) 2003-08-13
MXPA03003980A (es) 2003-08-19
AU2001225625B2 (en) 2006-06-15
BR0017367A (pt) 2003-10-07
CA2428012A1 (en) 2002-05-10
KR20040004431A (ko) 2004-01-13
NZ525487A (en) 2004-11-26
NO20032006D0 (no) 2003-05-05
NO20032006L (no) 2003-07-01

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
AU8622101A (en) Remedies for ischemic diseases
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
TWI345975B (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
GB0004531D0 (en) The treatment of respiratory diseases
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2562501A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
GB0001710D0 (en) Therapeutic treatment
IL150290A (en) Use of mirtazapine for preparation of a medicament for the treatment of sleep disorders
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
WO2002083083A3 (en) Pharmaceutically active compounds and methods of use
AU8339301A (en) Compounds for the treatment of addictive disorders
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AU2096002A (en) Therapeutic treatment
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
HUP0300717A3 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF